Pinitol and derivatives thereof for the treatment of metabolic disorders

• US 5,550,166 A
• Filed: 03/17/1995
• Issued: 08/27/1996
• Est. Priority Date: 03/17/1995
• Status: Expired due to Fees

• Current Assignee: Washington University In St Louis
• Original Assignee: Washington University In St Louis
• Inventors: Sherman, William R., Ostlund, Richard E.
• Primary Examiner(s): JORDAN, KIMBERLY R
• Application Number:
  US08/407,430
• Time in Patent Office: 529 Days
• Field of Search: 514/715, 514/866
• US Class Current: 514/715
• CPC Class Codes: A61K 31/075 Ethers or acetals
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 3/08 for glucose homeostasis pancreatic hormones A61P5/48

Abstract

Pinitol and derivatives and metabolites thereof are useful in nutritional and medicinal compositions for treating conditions associated with insulin resistance, such as diabetes mellitus and its chronic complications; obesity; hyperlipidemias and dyslipidemias atherosclerosis; hypertension; cardiovascular disease; AIDS; cancer; wasting/cachexia; sepsis; trauma associated with burns, malnutrition, and stress; aging; lupus and other autoimmune diseases; endocrine disease; hyperuricemia, polycystic ovary syndrome and complications arising from athletic activity or inactivity.

Claims

1. A composition useful in treating conditions of insulin resistance, hyperlipidemia or dyslipidemia in a mammal comprising an effective amount of pinitol or a derivative or metabolite thereof.

2. The composition of claim 1 wherein said composition is an orally ingestible nutritional supplement.

3. The composition of claim 1 wherein said composition is an orally ingestible medicament.

4. The composition of claim 1 wherein said composition is a liquid suitable for intravenous injection.

5. The composition of claim 1 wherein composition is in a dosage form providing 0.1 milligram to 1.0 gram/day of said pinitol, derivative or metabolite thereof per kilogram of body weight of said mammal.

6. The composition of claim 5 wherein said dosage form provides 1 to 10 milligrams/day of said pinitol, derivative or metabolite thereof per kilogram of body weight of said mammal.

7. The composition of claim 1 wherein said composition is effective in improving insulin sensitivity associated with hyperinsulinemia, insulin-stimulated glucose uptake, and impaired glucose tolerance.

8. The composition of claim 1 wherein said composition is effective in lowering plasma glucose levels.

9. The composition of claim 1 wherein said composition is effective in lowering plasma insulin levels.

10. The composition of claim 1 wherein said composition is effective in improving plasma lipid and lipoprotein levels by reducing triglycerides or low density lipoprotein cholesterol or by increasing high density lipoprotein cholesterol.

11. The composition of claim 1 wherein said pinitol, derivative or metabolite thereof is selected from the group consisting of pinitol, pinitol glycosides, pinitol phospholipids, esterified pinitol, lipid-bound pinitol, pinitol phosphates and pinitol phytates and mixtures thereof.

12. The composition of claim 1 wherein said mammal is a Homo sapien.

13. The composition of claim 1 wherein said composition is effective in lowering plasma lipid levels.

14. The composition of claim 1 wherein said composition is effective in decreasing plasma triglycerides levels.

15. A method of treating conditions of insulin resistance in a mammal comprising administering an effective amount of pinitol or a derivative or metabolite thereof.

16. The method of claim 15 wherein said mammal is a Homo sapien.

17. The method of claim 15 wherein said effective amount is 0.1 milligram to 1.0 grams per kilogram of body weight per day.

18. The method of claim 15 wherein said effective amount is 1 to 10 milligrams per kilogram of body weight per day.

19. The method of claim 15 wherein pinitol or derivative or metabolite is administered orally.

20. The method of claim 15 wherein said insulin resistance is associated with diabetes mellitus and its chronic complications;

obesity;

hyperlipidemias and dyslipidemias;

atherosclerosis;

hypertension;

cardiovascular disease;

AIDS;

cancer;

wasting/cachexia;

sepsis;

trauma associated with burns, malnutrition, and stress;

aging;

lupus and other autoimmune diseases;

endocrine disease;

hyperuricemia, polycystic ovary syndrome and complications arising from athletic activity.

21. The method of claim 15 wherein said pinitol, derivative or metabolite thereof is selected from the group consisting of pinitol, pinitol glycosides, pinitol phospholipids, esterified pinitol, lipid-bound pinitol, pinitol phosphates and pinitol phytates and mixtures thereof.

22. The method of claim 15 wherein said pinitol, or derivative or metabolite thereof is administered as multiple doses or continuous doses for a period of 1 day or longer.

23. The method of claim 15 wherein said pinitol, derivative or metabolite thereof is administered as multiple doses or continuous doses for a period of 3 days or longer.